コーパス検索結果(共起頻度の集計）
検索語: render cells
ヒット件数: 252
| 一般的な頻出語を「文章内」のリストから除外しています |
| 2語前 |
1語前 |
|
1語後 |
2語後 |
|
文章内 |
| of |
28 |
and |
38 |
|
resistant |
45 |
to |
136 |
|
resistant |
69 |
| and |
9 |
to |
16 |
|
more |
40 |
sensitive |
33 |
|
sensitive |
63 |
| sufficient |
5 |
that |
11 |
|
sensitive |
20 |
susceptible |
18 |
|
expression |
52 |
| in |
5 |
can |
9 |
|
susceptible |
19 |
resistant |
17 |
|
induced |
47 |
| 1 |
4 |
also |
8 |
|
hypersensitive |
15 |
in |
5 |
|
apoptosis |
46 |
| gene |
3 |
expression |
6 |
|
highly |
10 |
on |
3 |
|
cell |
42 |
| protein |
3 |
which |
5 |
|
insensitive |
8 |
responsive |
3 |
|
susceptible |
38 |
| the |
3 |
thereby |
5 |
|
less |
7 |
more |
3 |
|
cells |
35 |
| by |
3 |
gene |
5 |
|
refractory |
6 |
toward |
2 |
|
protein |
27 |
| repair |
3 |
by |
4 |
|
permissive |
5 |
capable |
2 |
|
dna |
26 |
| rna |
3 |
but |
3 |
|
vulnerable |
4 |
and |
2 |
|
stress |
24 |
| not |
3 |
cells |
3 |
|
unable |
4 |
of |
2 |
|
growth |
23 |
| growth |
2 |
function |
3 |
|
tolerant |
4 |
factor |
1 |
|
mediated |
23 |
| mechanism |
2 |
mutant |
3 |
|
dependent |
3 |
insensitive |
1 |
|
mutations |
20 |
| but |
2 |
1 |
3 |
|
responsive |
3 |
adaptable |
1 |
|
loss |
20 |
| complex |
2 |
torc2 |
2 |
|
temperature |
3 |
mice |
1 |
|
effects |
20 |
| expression |
2 |
thus |
2 |
|
partially |
3 |
providing |
1 |
|
gene |
19 |
| with |
2 |
network |
2 |
|
hyperresponsive |
3 |
bvr |
1 |
|
activation |
17 |
| changes |
2 |
ctr1 |
2 |
|
viable |
2 |
dependent |
1 |
|
response |
15 |
| mutations |
2 |
activity |
2 |
|
and |
2 |
apoptosis |
1 |
|
hypersensitive |
15 |
| madd |
2 |
loss |
2 |
|
significantly |
2 |
vulnerable |
1 |
|
pathway |
15 |
| signaling |
2 |
may |
2 |
|
able |
2 |
deficient |
1 |
|
c |
15 |
| or |
2 |
vivo |
2 |
|
tumorigenic |
2 |
permissive |
1 |
|
mutant |
15 |
| dna |
2 |
interference |
2 |
|
cold |
2 |
with |
1 |
|
dependent |
14 |
| synthesis |
2 |
overexpression |
2 |
|
capable |
2 |
100 |
1 |
|
s |
14 |
| adhesins |
1 |
phenotypes |
1 |
|
inviable |
1 |
prolonged |
1 |
|
damage |
14 |
| positioning |
1 |
nhej |
1 |
|
growth |
1 |
or |
1 |
|
depletion |
13 |
| tic |
1 |
ala537val |
1 |
|
largely |
1 |
high |
1 |
|
function |
13 |
| conditions |
1 |
cas |
1 |
|
increasingly |
1 |
for |
1 |
|
replication |
13 |
| cancer |
1 |
hsf1 |
1 |
|
nonmotile |
1 |
diverse |
1 |
|
inhibition |
13 |
| translation |
1 |
diphthamide |
1 |
|
exquisitely |
1 |
tissues |
1 |
|
infection |
13 |
| this |
1 |
eef2 |
1 |
|
maximally |
1 |
photosynthetic |
1 |
|
inhibitor |
13 |
| decreases |
1 |
molecule |
1 |
|
accumulating |
1 |
|
|
|
whereas |
13 |
| cdt1 |
1 |
line |
1 |
|
glucose |
1 |
|
|
|
trail |
12 |
| termini |
1 |
depletion |
1 |
|
to |
1 |
|
|
|
repair |
12 |
| morphology |
1 |
arginylation |
1 |
|
retinoid |
1 |
|
|
|
ifn |
12 |
| represses |
1 |
in |
1 |
|
particularly |
1 |
|
|
|
overexpression |
12 |
| chromatin |
1 |
synthesis |
1 |
|
functionally |
1 |
|
|
|
agents |
11 |
| small |
1 |
effect |
1 |
|
trail |
1 |
|
|
|
tumor |
11 |
| cell |
1 |
overload |
1 |
|
supersensitive |
1 |
|
|
|
alpha |
11 |
| dysfunction |
1 |
knockdown |
1 |
|
hyporesponsive |
1 |
|
|
|
cycle |
11 |
| mtp |
1 |
enzyme |
1 |
|
either |
1 |
|
|
|
mutation |
11 |
| fs |
1 |
iii |
1 |
|
thermosensitive |
1 |
|
|
|
resistance |
11 |
| inlb |
1 |
flga1 |
1 |
|
infected |
1 |
|
|
|
both |
11 |
| rates |
1 |
ssa1 |
1 |
|
immobile |
1 |
|
|
|
arrest |
11 |
| required |
1 |
acidosis |
1 |
|
30 |
1 |
|
|
|
deletion |
10 |
| hyperinduction |
1 |
aqp2 |
1 |
|
antiapoptotic |
1 |
|
|
|
highly |
10 |
| lto1 |
1 |
deficiency |
1 |
|
specifically |
1 |
|
|
|
activity |
10 |
| negative |
1 |
alc1 |
1 |
|
immortal |
1 |
|
|
|
tnf |
10 |
| transport |
1 |
system |
1 |
|
e1a |
1 |
|
|
|
treatment |
10 |
| cells |
1 |
xpf |
1 |
|
hyperelongated |
1 |
|
|
|
suggesting |
10 |
| finally |
1 |
ecms |
1 |
|
with |
1 |
|
|
|
levels |
10 |
| promoter |
1 |
bak |
1 |
|
defective |
1 |
|
|
|
kinase |
10 |
| aquaglyceroporin |
1 |
transcription |
1 |
|
thermoresistant |
1 |
|
|
|
insensitive |
9 |
| orai1 |
1 |
antifungals |
1 |
|
strikingly |
1 |
|
|
|
suggest |
9 |
| domain |
1 |
tolc |
1 |
|
nonfunctional |
1 |
|
|
|
effect |
9 |
| efflux |
1 |
155 |
1 |
|
from |
1 |
|
|
|
cancer |
9 |
| ercc1 |
1 |
v1 |
1 |
|
nonphotosynthetic |
1 |
|
|
|
survival |
9 |
| soft |
1 |
p16 |
1 |
|
much |
1 |
|
|
|
deficiency |
9 |
| bax |
1 |
formation |
1 |
|
non |
1 |
|
|
|
signaling |
9 |
| mice |
1 |
antioxidant |
1 |
|
relatively |
1 |
|
|
|
sufficient |
9 |
| receptors |
1 |
ikkepsilon |
1 |
|
|
|
|
|
|
either |
9 |
| mediated |
1 |
igf1r |
1 |
|
|
|
|
|
|
absence |
9 |
| program |
1 |
progression |
1 |
|
|
|
|
|
|
death |
9 |
| autophagosome |
1 |
transport |
1 |
|
|
|
|
|
|
receptor |
9 |
| load |
1 |
interface |
1 |
|
|
|
|
|
|
factor |
8 |
| sequestering |
1 |
pcbp2 |
1 |
|
|
|
|
|
|
inhibitors |
8 |
| hgf |
1 |
hnoa1 |
1 |
|
|
|
|
|
|
p53 |
8 |
| mir |
1 |
however |
1 |
|
|
|
|
|
|
knockdown |
8 |
| reduced |
1 |
telophase |
1 |
|
|
|
|
|
|
mechanism |
8 |
| functions |
1 |
iap2 |
1 |
|
|
|
|
|
|
synthesis |
8 |
| powerful |
1 |
mdm2 |
1 |
|
|
|
|
|
|
show |
8 |
| phase |
1 |
sirna |
1 |
|
|
|
|
|
|
phosphorylation |
8 |
| nuclear |
1 |
proteins |
1 |
|
|
|
|
|
|
signal |
8 |
| bipolarity |
1 |
factors |
1 |
|
|
|
|
|
|
type |
8 |
| metabolism |
1 |
rnas |
1 |
|
|
|
|
|
|
virus |
8 |
| migration |
1 |
tipin |
1 |
|
|
|
|
|
|
er |
8 |
| secreted |
1 |
p65 |
1 |
|
|
|
|
|
|
disruption |
8 |
| dimerization |
1 |
prb |
1 |
|
|
|
|
|
|
beta |
8 |
| pten |
1 |
dia2 |
1 |
|
|
|
|
|
|
apoptotic |
8 |
| did |
1 |
stimulation |
1 |
|
|
|
|
|
|
reduced |
8 |
| c |
1 |
sv |
1 |
|
|
|
|
|
|
results |
7 |
| activities |
1 |
rna |
1 |
|
|
|
|
|
|
using |
7 |
| proteins |
1 |
mcga3 |
1 |
|
|
|
|
|
|
small |
7 |
| protection |
1 |
levels |
1 |
|
|
|
|
|
|
oxidative |
7 |
| two |
1 |
repair |
1 |
|
|
|
|
|
|
thus |
7 |
| export |
1 |
adhesion |
1 |
|
|
|
|
|
|
vitro |
7 |
| tfg2 |
1 |
mitochondria |
1 |
|
|
|
|
|
|
required |
7 |
| interference |
1 |
puma |
1 |
|
|
|
|
|
|
less |
7 |
| accumulation |
1 |
oligomer |
1 |
|
|
|
|
|
|
permissive |
7 |
| prmt2 |
1 |
altered |
1 |
|
|
|
|
|
|
i |
7 |
| stress |
1 |
c53 |
1 |
|
|
|
|
|
|
domains |
7 |
| chaperone |
1 |
cip1 |
1 |
|
|
|
|
|
|
checkpoint |
7 |
| cdr1 |
1 |
loop |
1 |
|
|
|
|
|
|
kinases |
7 |
| hypoxia |
1 |
doxycycline |
1 |
|
|
|
|
|
|
contrast |
7 |
| tlr2 |
1 |
hsnm1b |
1 |
|
|
|
|
|
|
regulation |
7 |
| denn |
1 |
it |
1 |
|
|
|
|
|
|
ii |
7 |
| hairpin |
1 |
atp2c1 |
1 |
|
|
|
|
|
|
changes |
6 |
| normal |
1 |
traf2 |
1 |
|
|
|
|
|
|
caused |
6 |
| diseases |
1 |
cds1 |
1 |
|
|
|
|
|
|
cisplatin |
6 |
| much |
1 |
proteolysis |
1 |
|
|
|
|
|
|
high |
6 |
| s2d |
1 |
ccr5 |
1 |
|
|
|
|
|
|
ability |
6 |
| osbp |
1 |
atfx |
1 |
|
|
|
|
|
|
formation |
6 |
| glycoprotein |
1 |
event |
1 |
|
|
|
|
|
|
binding |
6 |
| are |
1 |
domain |
1 |
|
|
|
|
|
|
up |
6 |
| proliferation |
1 |
p110alpha |
1 |
|
|
|
|
|
|
cellular |
6 |
| factor |
1 |
flip |
1 |
|
|
|
|
|
|
independent |
6 |
| upr |
1 |
sulfoximine |
1 |
|
|
|
|
|
|
however |
6 |
| waf1 |
1 |
could |
1 |
|
|
|
|
|
|
does |
6 |
| dj |
1 |
dichlorobenzoyloxymethylketone |
1 |
|
|
|
|
|
|
responsive |
6 |
| activation |
1 |
myocytes |
1 |
|
|
|
|
|
|
gamma |
6 |
| either |
1 |
ddi1p |
1 |
|
|
|
|
|
|
specific |
6 |
| binding |
1 |
inhibitor |
1 |
|
|
|
|
|
|
akt |
6 |
| possibly |
1 |
phenylalanine |
1 |
|
|
|
|
|
|
myc |
6 |
| sites |
1 |
jnk |
1 |
|
|
|
|
|
|
refractory |
6 |
| protons |
1 |
arv1 |
1 |
|
|
|
|
|
|
against |
6 |
| infection |
1 |
cx43 |
1 |
|
|
|
|
|
|
tgf |
6 |
| esc4p |
1 |
process |
1 |
|
|
|
|
|
|
n |
6 |
| motif |
1 |
damage |
1 |
|
|
|
|
|
|
two |
6 |
| reducing |
1 |
disruption |
1 |
|
|
|
|
|
|
bcl |
6 |
| it |
1 |
e1a |
1 |
|
|
|
|
|
|
wild |
6 |
| that |
1 |
ski |
1 |
|
|
|
|
|
|
addition |
6 |
| raf |
1 |
modified |
1 |
|
|
|
|
|
|
partially |
6 |
| klf11 |
1 |
ikappabalpha |
1 |
|
|
|
|
|
|
vivo |
6 |
| vivo |
1 |
cbl |
1 |
|
|
|
|
|
|
increasing |
6 |
| fancf |
1 |
deletions |
1 |
|
|
|
|
|
|
active |
5 |
| ig20 |
1 |
integrins |
1 |
|
|
|
|
|
|
leukemia |
5 |
| subunit |
1 |
glutathione |
1 |
|
|
|
|
|
|
molecule |
5 |
| frameshifting |
1 |
peptides |
1 |
|
|
|
|
|
|
vulnerable |
5 |
| ghr |
1 |
dttox |
1 |
|
|
|
|
|
|
no |
5 |
| nor |
1 |
apparently |
1 |
|
|
|
|
|
|
evidence |
5 |
| neoplastic |
1 |
invariably |
1 |
|
|
|
|
|
|
reduction |
5 |
| src |
1 |
kinase |
1 |
|
|
|
|
|
|
translation |
5 |
| hat |
1 |
halobium |
1 |
|
|
|
|
|
|
enhanced |
5 |
| appears |
1 |
aag |
1 |
|
|
|
|
|
|
induce |
5 |
| efc25 |
1 |
|
|
|
|
|
|
|
|
necrosis |
5 |
| active |
1 |
|
|
|
|
|
|
|
|
sensitivity |
5 |
| substitution |
1 |
|
|
|
|
|
|
|
|
suggests |
5 |
| buthionine |
1 |
|
|
|
|
|
|
|
|
through |
5 |
| felv |
1 |
|
|
|
|
|
|
|
|
pi3k |
5 |
| 6 |
1 |
|
|
|
|
|
|
|
|
enhances |
5 |
| cardiac |
1 |
|
|
|
|
|
|
|
|
blocking |
5 |
| p |
1 |
|
|
|
|
|
|
|
|
mir |
5 |
| survival |
1 |
|
|
|
|
|
|
|
|
transformation |
5 |
| to |
1 |
|
|
|
|
|
|
|
|
inhibiting |
5 |
| kinase |
1 |
|
|
|
|
|
|
|
|
only |
5 |
| pathway |
1 |
|
|
|
|
|
|
|
|
human |
5 |
| dmp53 |
1 |
|
|
|
|
|
|
|
|
cyclin |
5 |
| kappab |
1 |
|
|
|
|
|
|
|
|
importantly |
5 |
| alone |
1 |
|
|
|
|
|
|
|
|
nf |
5 |
| zzz1 |
1 |
|
|
|
|
|
|
|
|
kappab |
5 |
| cdc2 |
1 |
|
|
|
|
|
|
|
|
mutants |
5 |
| p53 |
1 |
|
|
|
|
|
|
|
|
silencing |
5 |
| process |
1 |
|
|
|
|
|
|
|
|
negative |
5 |
| disease |
1 |
|
|
|
|
|
|
|
|
double |
5 |
| sse1 |
1 |
|
|
|
|
|
|
|
|
sites |
5 |
| rub1p |
1 |
|
|
|
|
|
|
|
|
significantly |
5 |
| chi |
1 |
|
|
|
|
|
|
|
|
hypoxia |
5 |
| p27 |
1 |
|
|
|
|
|
|
|
|
activated |
5 |
| found |
1 |
|
|
|
|
|
|
|
|
found |
5 |
| calreticulin |
1 |
|
|
|
|
|
|
|
|
temperature |
5 |
| top1 |
1 |
|
|
|
|
|
|
|
|
radiation |
5 |
| translocation |
1 |
|
|
|
|
|
|
|
|
thereby |
5 |
| beta3 |
1 |
|
|
|
|
|
|
|
|
ctr1 |
5 |
| is |
1 |
|
|
|
|
|
|
|
|
proteins |
5 |
| tola |
1 |
|
|
|
|
|
|
|
|
dr5 |
5 |
| ii |
1 |
|
|
|
|
|
|
|
|
rna |
5 |
| intracellular |
1 |
|
|
|
|
|
|
|
|
capable |
5 |
| shown |
1 |
|
|
|
|
|
|
|
|
subsequent |
5 |
| grp94 |
1 |
|
|
|
|
|
|
|
|
genes |
4 |
| toxic |
1 |
|
|
|
|
|
|
|
|
findings |
4 |
| resistance |
1 |
|
|
|
|
|
|
|
|
cause |
4 |
| t |
1 |
|
|
|
|
|
|
|
|
conditions |
4 |
| thymidine |
1 |
|
|
|
|
|
|
|
|
rate |
4 |
| 3 |
1 |
|
|
|
|
|
|
|
|
mrna |
4 |
| means |
1 |
|
|
|
|
|
|
|
|
reduces |
4 |
| h |
1 |
|
|
|
|
|
|
|
|
uv |
4 |
| mini |
1 |
|
|
|
|
|
|
|
|
irradiation |
4 |
|
|
|
|
|
|
|
|
|
|
further |
4 |
|
|
|
|
|
|
|
|
|
|
tyrosine |
4 |
|
|
|
|
|
|
|
|
|
|
agent |
4 |
|
|
|
|
|
|
|
|
|
|
regulated |
4 |
|
|
|
|
|
|
|
|
|
|
although |
4 |
|
|
|
|
|
|
|
|
|
|
autophagy |
4 |
|
|
|
|
|
|
|
|
|
|
other |
4 |
|
|
|
|
|
|
|
|
|
|
induces |
4 |
|
|
|
|
|
|
|
|
|
|
proliferation |
4 |
|
|
|
|
|
|
|
|
|
|
target |
4 |
|
|
|
|
|
|
|
|
|
|
drug |
4 |
|
|
|
|
|
|
|
|
|
|
ras |
4 |
|
|
|
|
|
|
|
|
|
|
mitochondrial |
4 |
|
|
|
|
|
|
|
|
|
|
study |
4 |
|
|
|
|
|
|
|
|
|
|
stable |
4 |
|
|
|
|
|
|
|
|
|
|
point |
4 |
|
|
|
|
|
|
|
|
|
|
il |
4 |
|
|
|
|
|
|
|
|
|
|
major |
4 |
|
|
|
|
|
|
|
|
|
|
increased |
4 |
|
|
|
|
|
|
|
|
|
|
dominant |
4 |
|
|
|
|
|
|
|
|
|
|
inhibit |
4 |
|
|
|
|
|
|
|
|
|
|
nuclear |
4 |
|
|
|
|
|
|
|
|
|
|
alone |
4 |
|
|
|
|
|
|
|
|
|
|
finally |
4 |
|
|
|
|
|
|
|
|
|
|
hsp90 |
4 |
|
|
|
|
|
|
|
|
|
|
protects |
4 |
|
|
|
|
|
|
|
|
|
|
iii |
4 |
|
|
|
|
|
|
|
|
|
|
promoter |
4 |
|
|
|
|
|
|
|
|
|
|
rescued |
4 |
|
|
|
|
|
|
|
|
|
|
unable |
4 |
|
|
|
|
|
|
|
|
|
|
defects |
4 |
|
|
|
|
|
|
|
|
|
|
component |
4 |
|
|
|
|
|
|
|
|
|
|
presence |
4 |
|
|
|
|
|
|
|
|
|
|
demonstrate |
4 |
|
|
|
|
|
|
|
|
|
|
stimuli |
4 |
|
|
|
|
|
|
|
|
|
|
her2 |
4 |
|
|
|
|
|
|
|
|
|
|
prior |
4 |
|
|
|
|
|
|
|
|
|
|
ikkepsilon |
4 |
|
|
|
|
|
|
|
|
|
|
transcription |
4 |
|
|
|
|
|
|
|
|
|
|
hiv |
4 |
|
|
|
|
|
|
|
|
|
|
one |
4 |
|
|
|
|
|
|
|
|
|
|
metabolism |
4 |
|
|
|
|
|
|
|
|
|
|
express |
4 |
|
|
|
|
|
|
|
|
|
|
endogenous |
4 |
|
|
|
|
|
|
|
|
|
|
progression |
4 |
|
|
|
|
|
|
|
|
|
|
identified |
4 |
|
|
|
|
|
|
|
|
|
|
novel |
4 |
|
|
|
|
|
|
|
|
|
|
early |
4 |
|
|
|
|
|
|
|
|
|
|
glutamine |
4 |
|
|
|
|
|
|
|
|
|
|
stimulation |
4 |
|
|
|
|
|
|
|
|
|
|
export |
4 |
|
|
|
|
|
|
|
|
|
|
did |
4 |
|
|
|
|
|
|
|
|
|
|
since |
4 |
|
|
|
|
|
|
|
|
|
|
tolerant |
4 |
|
|
|
|
|
|
|
|
|
|
indicating |
4 |
|
|
|
|
|
|
|
|
|
|
well |
4 |
|
|
|
|
|
|
|
|
|
|
drugs |
4 |
|
|
|
|
|
|
|
|
|
|
caffeine |
4 |
|
|
|
|
|
|
|
|
|
|
ig20 |
4 |
|
|
|
|
|
|
|
|
|
|
inhibitory |
4 |
|
|
|
|
|
|
|
|
|
|
decreased |
4 |
|
|
|
|
|
|
|
|
|
|
p |
4 |
|
|
|
|
|
|
|
|
|
|
t |
4 |
|
|
|
|
|
|
|
|
|
|
beta3 |
4 |
|
|
|
|
|
|
|
|
|
|
rrna |
4 |
|
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。